Publication: Comparison of an automated thermodynamic treatment system (lipiflow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction
Issued Date
2020-01-01
Resource Type
ISSN
22288082
Other identifier(s)
2-s2.0-85079198864
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Siriraj Medical Journal. Vol.72, No.1 (2020), 79-86
Suggested Citation
Wipawee Booranapong, Pinnita Prabhasawat, Suksri Chotikavanich, Sasima Tongsai, Patsathorn Naranunn, Wilaipun Thaweerattanasilp, Panida Kosrirukvongs Comparison of an automated thermodynamic treatment system (lipiflow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction. Siriraj Medical Journal. Vol.72, No.1 (2020), 79-86. doi:10.33192/Smj.2020.11 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/53811
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Comparison of an automated thermodynamic treatment system (lipiflow) and warm compresses for the treatment of moderate severity of meibomian gland dysfunction
Other Contributor(s)
Abstract
© 2020 Faculty of Medicine Siriraj Hospital, Mahidol University. Objective: To compare the efficacies of a single thermodynamic treatment system (LipiFlow®) and warm compresses used for 3 months in patients with a moderate severity of meibomian gland dysfunction (MGD). Methods: This prospective, randomized, controlled clinical study enrolled 28 patients (22 females, 6 males; mean age, 53.9 ± 14.8 years) diagnosed ashaving moderate MGD by plugging at the meibomian gland orifices between one-third and two-thirds of lid margins and at least one of the following: a Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score of 6-12; a lipid layer thickness (LLT) score of 40-70 Interferometric Color Units; upper eyelid meiboscore of 1-2; and 3-6 expressible meibomian glands (EMGs) in the lower eyelid. Both eyes of each patient were randomized into study and control eyes. Study eyes were treated with a single, 12-minute LipiFlow® system, while control eyes received 5-minute warm compresses twice daily for 3 months. The dry eyesymptoms, the number of EMGs, and LLTs were evaluated. Results: There were no significant differences in the dry eye symptoms, number of EMGs, and LLTs for both groups at baseline and at each follow-up. However, the total SPEED scores for the LipiFlow® group reduced significantly from baseline at each follow-up until 6 months. As to the warm compress group, the total SPEED scores reduced significantly from baseline at each follow-up until 3 months.Conclusion: The single LipiFlow® treatment and twice-daily warm compresses relieved the dry eye symptoms of patients with a moderate severity of MGD compared with their baseline symptoms, despite no statistical differences in the dry eye symptoms, number of EMGs, and LLTs of both treatments.